Author: admin

Qinux DizaDry Launches Portable Shoe Dryer Sterilizer

It’s common for footwear to deteriorate, especially in the area of the insoles, due to factors like sweat, moisture, and inadequate drying. When shoes or boots get wet, whether from sweat or external sources, and aren’t thoroughly dried, it creates an environment conducive to bacterial and fungal growth. Over time, this can lead to the breakdown of materials, including the insoles, causing them to deteriorate and potentially rot.

Qinux DizaDry emerges as a specialized electric shoe dryer meticulously crafted to provide comprehensive ventilation to footwear from within, utilizing hot air to ensure thorough and efficient drying. Tailored for periods of inclement weather when rain and snow render footwear damp, this innovative device offers an ideal solution to combat moisture and maintain shoe integrity.

Designed with precision, Qinux DizaDry boasts a user-friendly interface, allowing individuals to effortlessly dry their shoes with optimal efficiency. By circulating hot air throughout the interior of the footwear, it effectively evaporates moisture, leaving shoes dry and ready for use in a fraction of the time.

This electric shoe dryer is particularly beneficial for individuals living in regions prone to frequent precipitation or those engaging in outdoor activities where shoes are susceptible to becoming wet. Whether it’s hiking boots soaked from traversing muddy trails or sneakers dampened by unexpected rainfall, Qinux DizaDry offers a convenient and reliable method to restore footwear to its pristine condition.

Moreover, its compact and portable design ensures versatility and ease of use, making it suitable for home use or travel purposes. With Qinux DizaDry at their disposal, users can bid farewell to the inconvenience of damp footwear and confidently step out into any weather condition, knowing their shoes will remain dry and comfortable throughout the day.

By following the simple steps bellow, Qinux DizaDry provides a convenient and efficient solution for drying footwear, ensuring that shoes or boots remain dry and comfortable, especially during periods of wet weather.

  • Step 1: Insert Qinux DizaDry into the footwear that needs to be dried, ensuring it fits securely within the shoes or boots.
  • Step 2: Power On: Plug the device into a power source and activate it using the power switch or button located on the device.
  • Step 3: Hot Air Circulation: Qinux DizaDry generates hot air, which is then circulated throughout the interior of the footwear.
  • Step 4: Ventilation: The hot air is evenly distributed inside the shoes or boots, reaching all areas including the toe box, insoles, and uppers.
  • Step 5: Moisture Evaporation: The circulating hot air effectively evaporates any moisture present within the footwear, including sweat, rainwater, or snowmelt.
  • Step 6: Drying Process: Over time, the continuous circulation of hot air gradually dries the footwear, removing all moisture.
  • Step 7: Completion: Once the drying process is complete, power off the device and remove it from the footwear.
  • Step 8: Ready for Use: The footwear is now dry and ready for immediate use, ensuring comfort and protection for the wearer.

Qinux DizaDry offers a range of features designed to provide efficient, convenient, and reliable drying for footwear, ensuring that shoes and boots remain dry, comfortable, and ready for use in any weather condition. Here are the features of Qinux DizaDry:

Efficient Drying: Utilizes hot air circulation to efficiently dry footwear from the inside out, eliminating moisture and reducing the risk of odors and mold.

Compact and Portable: Designed to be compact and lightweight, making it easy to carry and store, ideal for home use or travel.

Versatile Compatibility: Fits into a wide range of footwear sizes and styles, accommodating various types of shoes, boots, and athletic footwear.

User-Friendly Operation: Simple power switch or button for easy activation and deactivation, with intuitive controls for hassle-free use.

Safe and Reliable: Built-in safety features to prevent overheating or damage to footwear, ensuring safe operation.

Energy-Efficient: Designed to use minimal power while providing effective drying, reducing energy consumption and saving on electricity costs.

Durable Construction: Made from high-quality materials for long-lasting durability and reliability, ensuring years of use.

Multipurpose Usage: Can also be used to dry gloves, socks, and other small garments or accessories, offering versatility in drying options.

Quiet Operation: Operates quietly, allowing for discreet use without disturbing others nearby.

Effortless Maintenance: Easy to clean and maintain, with removable components for convenient upkeep and longevity of the device.

  • Effectively eliminates moisture from footwear, reducing drying time and preventing discomfort.
  • Helps prevent the formation of unpleasant odors by thoroughly drying shoes and boots after wear.
  • Reduces the risk of mold and mildew growth by removing excess moisture from footwear.
  • Prolongs the lifespan of shoes and boots by preventing deterioration caused by moisture damage.
  • Compact and lightweight design allows for easy transport and use at home or while traveling.
  • Can be used with various types of footwear, including shoes, boots, and athletic shoes, for versatile drying options.
  • Operates with minimal power consumption, helping to save on electricity costs while providing effective drying.
  • Ensures dry and comfortable footwear, promoting foot health and overall comfort throughout the day,
  • Operates quietly, allowing for discreet use without causing disturbance to others nearby.
  • Easy to clean and maintain, with removable components for effortless upkeep and long-term durability.


At $89, Qinux DizaDry offers an affordable yet effective solution for maintaining dry and comfortable footwear. With this investment, individuals can elevate their shoe care routine, bidding farewell to the inconvenience of damp, uncomfortable shoes. The product is available in stock at its official website.

The device’s ease of use, quiet operation, and effective drying capabilities make it a highly recommended purchase for those seeking convenient and reliable footwear maintenance solutions. It accommodates any boot or shoe with ease, providing a snug fit for all footwear types. Moreover it helps maintain shoe and indoor hygiene by eliminating bacteria and bad smell from the shoes. Notably, its silent operation guarantees minimal disruption, allowing users to enjoy dry and warm shoes without disturbance. Overall, based on user experience, many find it to be a worthwhile investment, all glory to its efficient performance and user-friendly design.

Media Contact
Company Name: Qinux DizaDry
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://rebrand.ly/DizaDry

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Qinux DizaDry Launches Portable Shoe Dryer Sterilizer

Citation Vault: The Key to Local SEO Success

“Local Citations that Matter. Available Worldwide.”
Citation Vault (CV) is revolutionizing the way businesses approach local SEO with features designed to boost visibility & drive results. Unlike other directory sites, CV offers 300 structured local citations, 300 do-follow backlinks, & 300 GMB map embeds, ensuring accuracy & consistency across all online platforms. With a 14-day free trial and competitive pricing options, CV is the ultimate solution for businesses looking to unlock the power of local citations & dominate their local market.

Citation Vault, the leading service for businesses worldwide, is revolutionizing local citation management for both small business owners and online marketing agencies. In a market flooded with directory sites, Citation Vault stands out as the superior option, offering unmatched features and benefits that drive tangible results in local market visibility and SEO efforts.

Comprehensive SEO local citations play a pivotal role in establishing a business’s online authority and visibility, making it essential for businesses to invest in the right citation solution. Unlike other directory sites such as Yext, DashClicks, and SignUp, Citation Vault offers a comprehensive suite of features tailored to meet the unique needs of businesses worldwide plus they offer more power in their links than any other out there.

Key features of Citation Vault include:

  • 300 structured local citations
  • 300 do-follow backlinks from unique IPs
  • 300 GMB map embeds
  • YouTube video embed
  • Social media profile links
  • 300 profile pages with JSON Schema

This comprehensive suite of features is available for unlimited locations at a competitive monthly cost of $297 or for a single location at $49 per month, with an option for annual payment that includes two free months. Additionally, Citation Vault offers a 14-day free trial, allowing businesses to experience the platform’s benefits firsthand.

One of Citation Vault’s standout features is its ability to generate 300 unique business descriptions, mitigating the risk of duplicate content suppression and saving businesses valuable time and resources. With 100% NAP accuracy and custom URL structures that include essential business information, Citation Vault ensures consistency across all directory sites and drives more traffic to businesses’ Google My Business profiles.

“While other directory sites offer similar services, Citation Vault sets itself apart with its comprehensive suite of features and unparalleled effectiveness in driving local market visibility,” says Jennifer Braudway, managing partner of Citation Vault. “With Citation Vault, businesses can expect tangible results and a significant boost in their online presence.”

In conclusion, Citation Vault emerges as the top contender for businesses seeking a comprehensive and effective local citation solution. With its unmatched features, competitive pricing, and proven track record of success, Citation Vault is the ultimate choice for businesses worldwide looking to unlock the power of local citations and dominate their local market.

For more information and to start your free trial, visit Citation Vault. 

                                                            

Media Contact
Company Name: Citation Vault
Contact Person: Jennifer and Andy Braudway
Email: Send Email
Phone: 713-808-1654
Address:7331 Emerald Glade Lane
City: Humble
State: TX
Country: United States
Website: citationvault.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Citation Vault: The Key to Local SEO Success

Micah Hainin: Redefining Success in Marketing and Social Media Influence at a Young Age

At just 20 years old, Micah Hainin has already made waves in the marketing industry and social media landscape, proving that age is no barrier to success. As the founder and CEO of Cloud Station’s, Micah has demonstrated remarkable acumen and innovation, carving out a niche for himself in the competitive world of digital marketing.

From humble beginnings, Micah’s journey to becoming a prominent figure in the marketing realm is nothing short of inspirational. With a keen understanding of consumer behavior and emerging trends, he has propelled his company to the forefront of the industry, earning accolades and recognition along the way.

What sets Micah apart is not only his youth but also his innate ability to leverage social media platforms to amplify his message and reach a global audience. With an impressive following on Instagram, where he shares insights and behind-the-scenes glimpses into his entrepreneurial journey, Micah has cemented his status as a social media influencer.

“I believe in the power of authenticity and transparency,” says Micah. “Through my own experiences and challenges, I aim to inspire others to pursue their passions fearlessly and embrace their uniqueness.”

Micah’s dedication to his craft and his unwavering commitment to excellence have earned him admiration and respect from peers and industry veterans alike. His strategic marketing approach and creative flair have resulted in numerous successful campaigns for clients across various sectors.

As Micah continues to evolve and grow, he remains steadfast in his mission to redefine success and empower the next generation of entrepreneurs. With his infectious enthusiasm and boundless energy, he is poised to make an even greater impact in the years to come.

Follow Micah Hainin on Instagram:

Media Contact
Company Name: Cloud Station’s
Contact Person: Micah Hainin
Email: Send Email
City: Fairfax
State: Virginia
Country: United States
Website: www.instagram.com/micahhainin

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Micah Hainin: Redefining Success in Marketing and Social Media Influence at a Young Age

Ingrid Lamarr Releases “The 15-Minute Air Fryer Cookbook for Beginners” – Simplifying Healthy Cooking

Ingrid Lamarr’s new book offers easy 15-minute air fryer recipes for healthy and delicious meals, catering to all cooking levels and diets.

Author Ingrid Lamarr introduces “The 15-Minute Air Fryer Cookbook for Beginners”, a comprehensive guide to enhance the cooking experience with air frying techniques. This cookbook is designed for both beginners and experienced cooks, providing a straightforward approach to preparing tasty and healthy meals.

Lamarr’s latest work focuses on the ease of cooking without sacrificing nutrition or flavor. The book features a range of recipes, from breakfasts to desserts, which can be prepared in 15 minutes or less using an air fryer. It addresses various dietary preferences and needs, including vegetarian and gluten-free options, making it a versatile addition to any kitchen.

“Transform your meals and your health with just 15 minutes and an air fryer,” Ingrid Lamarr states, highlighting the efficiency and health benefits of air frying. “Our goal is to make healthy eating a delightful experience, not a chore,” she continues, reflecting her commitment to encouraging healthier eating habits through enjoyable cooking practices.

Ingrid Lamarr channels her deep love and expertise in culinary arts into this guide, focusing on the simplicity and enjoyment of health-conscious cooking. She highlights the benefits of mindful culinary practices and their positive impact on wellness and dietary habits. By incorporating guidance on selecting and maximizing the use of air fryers, she presents an all-encompassing manual ideal for novice users. Her approach addresses the fast-paced nature of contemporary life, providing a blend of speed, nutrition, and palatability that caters to the needs of time-constrained cooks and health enthusiasts alike. Lamarr aims to encourage a transition to more deliberate and healthful cooking techniques, enhancing life quality through better food choices.

“The 15-Minute Air Fryer Cookbook for Beginners” emerges as an essential tool for those aiming to reduce kitchen labor without compromising on the diversity and appeal of their meals. It highlights the air fryer’s role in preparing dishes swiftly while reducing fat content, promoting a shift towards wholesome living with ease. Lamarr’s collection of recipes demonstrates that convenience and health can coexist within the culinary realm, providing a foundation for lasting lifestyle improvements. By equipping readers with the knowledge to navigate the world of air frying, Lamarr empowers them to redefine fast food as a healthy, accessible option in their daily lives.

Get The 15-Minute Air Fryer Cookbook for Beginners by Ingrid Lamarr on Amazon: https://a.co/d/3PW5VWR

About Ingrid Lamarr.

Ingrid Lamarr is an author driven by her deep love for cooking and a desire to share her culinary insights. Her work is characterized by her hands-on approach and dedication to creating enjoyable cooking experiences. With “The 15-Minute Air Fryer Cookbook for Beginners”, Lamarr hopes to inspire others to explore healthier cooking options without feeling overwhelmed.

For updates, follow Ingrid Lamarr’s Facebook Page.

Media Contact
Company Name: Ingrid Lamarr
Contact Person: Ingrid Lamarr
Email: Send Email
Country: United States
Website: a.co/d/3PW5VWR

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ingrid Lamarr Releases \”The 15-Minute Air Fryer Cookbook for Beginners\” – Simplifying Healthy Cooking

Introducing Rummy’s Beach Club: A Unique Haven for Dogs and Their Owners Year Round

“Rummy’s Beach Club offers the Best Dog Swimming in Houston and surrounding areas.”
Rummy’s Beach Club in Houston offers an exclusive dog-friendly experience all year long. Whether you want to boost your dog’s water skills, teach them to swim, enjoy the one-acre dog park, or try dock jumping, we’ve got you covered. Our unique club provides support for dogs uncomfortable with water, with a beach entry and life jackets for safety. Enjoy VIP amenities like dock diving, a heated pool year-round, swimming lessons, and professional photography to capture special moments.

Spring, TX – Are you looking to break the routine with your beloved pets and create unforgettable memories together? While animals thrive on routine, there’s joy and mental stimulation in exploring new experiences. Try out Rummy’s Beach Club, your go-to destination for a one-of-a-kind experience that will leave tails wagging!  Customers enjoy the 1 acre dog park and private pool experience year round with a winter dome, heated pool, and a space for changing.  Don’t miss out on great experiences like these with your fur babies.

Rummy’s Beach Club, nestled in the heart of Houston and its surrounding areas, offers a diverse range of activities to cater to all your canine companion’s needs. Whether you want to boost your dog’s water confidence, teach them to swim, engage in exhilarating dock jumping, or simply enjoy our stunning dog park, Rummy’s Beach Club has you covered.

For older dogs or pups dealing with arthritis, the therapeutic benefits of swimming are immeasurable. And for the younger ones, we’re here to help them become proficient swimmers and ensure they’re thoroughly worn out by the end of the day!

Best Dog Swimming: At Rummy’s Beach Club, all dogs and clients are welcome. We understand that some dogs may be uncomfortable or fearful of water, which is why we provide extra support and tips to help both the pup and their parent. Our pool features a beach entry and a large shallow area, perfect for gradually introducing your pup to the water in a positive and comfortable manner. We also offer life jackets to ensure safety and build trust with our furry friends.

Private Dog Swim: One of the standout features of Rummy’s Beach Club is its exclusivity. It’s a private club, ensuring that you and your dog(s) have the VIP experience you deserve. This makes it ideal for older dogs, dogs with health issues, or dogs with behavioral challenges. Our amenities include dock diving, year-round swimming with a heated pool, swimming lessons, photography and video services, a retail store, and a one-acre dog park for sniffing and seeking fun.

Dog Photography & Video: Capture those precious moments with your pup at Rummy’s Beach Club. We provide professional photos and videos of your session, turning your dog’s water adventures into lasting memories. We even offer underwater photography for those pups that love to dive. And during the holidays, we set up a themed photo booth for an extra special touch.

Winter Swimming: Don’t let the cold weather stop your pup from having a blast. In the winter, we protect you and your furry friend from the elements with our Winter Dome, keeping the pool heated and the water warm. Swimming at Rummy’s Beach Club is a year-round delight, benefiting dogs of all ages.

Private Dog Park: Let your pup run free and off-leash in our one-acre dog park, where they can engage in various activities that bring them joy and excitement. It’s a place where dogs can exercise, socialize, and simply be themselves, creating a lively atmosphere for both dogs and their owners.

Rummy’s Retail Store: After a fun dip or a session of dock jumping, visit our retail store for toys, treats, dog food, and fresh ingredients to enhance your pup’s meals. Don’t forget to check out our special designed shirts!

9 Reasons To Visit Rummy’s Beach Club:

  1. Private VIP Session with you and your pups.
  2. Heated walk-in Pool.
  3. Shallow swimming.
  4. Dog Park – 1 acre of fun!
  5. Winter Swimming with the Winter Dome.
  6. Dock Diving (10’x 6′ dock).
  7. Fun Photography & Video.
  8. Experienced Staff & Owner.
  9. Retail Store – shirts, treats, food, toys, & more!

Rummy’s Beach Club is a haven for dog lovers of all ages. Swimming with your dog is a low-impact exercise that offers numerous benefits, making it suitable for adults at any stage of life. It’s an activity that promotes fitness, flexibility, relaxation, and stress relief.

About Rummy’s Beach Club: Founded in 2009 by Lisa Goebel, Rummy’s Beach Club is a unique establishment inspired by the remarkable journey of a rescued Siberian Husky named Rummy. Lisa and Rummy’s transformational journey led to the vision of creating a place where dogs and their owners can forge meaningful connections, guided by compassion and a commitment to improving the lives of dogs everywhere.

Visit Rummy’s Beach Club today and embark on an exclusive aquatic retreat with your canine companion. Your journey to creating lasting memories starts here!

Media Contact
Company Name: Rummy’s Beach Club
Contact Person: Lisa Goebel
Email: Send Email
Phone: +17134463805
Address:22111 Fields Lane
City: Spring
State: Texas
Country: United States
Website: rummysbeachclub.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Introducing Rummy\’s Beach Club: A Unique Haven for Dogs and Their Owners Year Round

Psoriatic Arthritis Pipeline Insights Report 2024 | Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics,Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech and others

DelveInsight’s, “Psoriatic Arthritis Pipeline Insight 2024” report provides comprehensive insights about 50+ Psoriatic Arthritis companies and 50+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriatic Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Psoriatic Arthritis Pipeline Report

  • DelveInsight’s Psoriatic Arthritis pipeline report depicts a robust space with 50+ Psoriatic Arthritis companies working to develop 50+ pipeline therapies for Psoriatic Arthritis treatment.
  • The leading companies working in the Psoriatic Arthritis Market include Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and others.
  • Promising Psoriatic Arthritis Pipeline Therapies in the various stages of development include NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others.
  • September 2023: ACELYRIN Inc. announced a study of phase 2 & 3 clinical trials for Izokibep. Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
  • September 2023: Novartis Pharmaceuticals announced a study of phase 3 clinical trials for Secukinumab and Ustekinumab. The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment.

 

Request a sample and discover the recent advances in Psoriatic Arthritis Treatment Drugs @ Psoriatic Arthritis Pipeline Report

 

In the Psoriatic Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Psoriatic Arthritis Overview

Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies.

 

Find out more about Psoriatic Arthritis Therapeutics Assessment @ Psoriatic Arthritis Preclinical and Discovery Stage Products

 

Psoriatic Arthritis Emerging Drugs Profile

  • ABT-494: AbbVie
  • Risankizumab: Abbvie

 

Psoriatic Arthritis Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Psoriatic Arthritis therapies. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Registered include, Abbvie.

 

Learn more about the emerging Psoriatic Arthritis Pipeline Therapies @ Psoriatic Arthritis Clinical Trials Assessment

 

Scope of the Psoriatic Arthritis Pipeline Report

  • Coverage- Global
  • Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Psoriatic ArthritisTherapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Psoriatic Arthritis Companies- Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and others.
  • Psoriatic Arthritis Pipeline Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others.

 

Dive deep into rich insights for new drugs for Psoriatic Arthritis Treatment, Visit @ Psoriatic Arthritis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Psoriatic Arthritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Psoriatic Arthritis– DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Psoriatic Arthritis Collaboration Deals
  9. Late Stage Products (Registered/Launch)
  10. MYL-1401A: Mylan
  11. Drug profiles in the detailed report…..
  12. Late Stage Products (Registered)
  13. ABT-494: AbbVie
  14. Drug profiles in the detailed report…..
  15. Late Stage Products (Preregistration)
  16. Tildrakizumab: Sun Pharma Global
  17. Drug profiles in the detailed report…..
  18. Late Stage Products (Phase III)
  19. Filgotinib: Gilead Sciences
  20. Drug profiles in the detailed report…..
  21. Mid Stage Products (Phase II)
  22. PF-06700841: Pfizer
  23. Drug profiles in the detailed report…..
  24. Early Stage Products (Phase I)
  25. BAT2506: Bio-Thera Solutions
  26. Drug profiles in the detailed report…..
  27. IND Stage Products
  28. KPG-612: Kangpu Biopharmaceuticals
  29. Drug profiles in the detailed report…..
  30. Preclinical Stage Products
  31. ALPN 101: Alpine Immune Sciences
  32. Drug profiles in the detailed report…..
  33. Discovery Stage Products
  34. DNX 514: DNX Biopharmaceuticals
  35. Inactive Products
  36. Psoriatic Arthritis Key Companies
  37. Psoriatic Arthritis Key Products
  38. Psoriatic Arthritis- Unmet Needs
  39. Psoriatic Arthritis- Market Drivers and Barriers
  40. Psoriatic Arthritis- Future Perspectives and Conclusion
  41. Psoriatic Arthritis Analyst Views
  42. Psoriatic Arthritis Key Companies
  43. Appendix

 

For further information on the Psoriatic Arthritis Pipeline therapeutics, reach out to Psoriatic Arthritis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriatic Arthritis Pipeline Insights Report 2024 | Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics,Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech and others

Encephalopathy Pipeline Insights Report 2024 | Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, and others.

DelveInsight’s, “Encephalopathy Pipeline Insight 2024” report provides comprehensive insights about 70+ Encephalopathy companies and 70+ pipeline drugs in the Encephalopathy pipeline landscape. It covers the Encephalopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Encephalopathy Pipeline Report

  • DelveInsight’s Encephalopathy pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Encephalopathy treatment.
  • The leading companies working in the Encephalopathy market include Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
  • Promising Encephalopathy Pipeline Therapies in the various stages of development include RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.
  • On April 2023, Bausch Health Americas Inc. announced a study of Phase 3 Clinical Trials for Rifaximin SSD. Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
  • On August 2023, ReAlta Life Sciences Inc. announced a study of Phase 2 Clinical Trials for RLS-0071. This is a Phase 2, two-stage, multisite, randomized, double-blind, placebo-controlled, multiple-ascending dose study of RLS-0071 to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in newborns with moderate or severe HIE undergoing therapeutic hypothermia.

 

Request a sample and discover the recent advances in Encephalopathy Treatment Drugs @ Encephalopathy Pipeline Report

 

The Encephalopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Encephalopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Encephalopathy clinical trial landscape.

 

Encephalopathy Overview

Encephalopathy is a broad term used to describe abnormal brain function or brain structure. (Encephalo= brain + pathy= disorder). The abnormality may be transient, recurrent, or permanent. The loss of brain function may be reversible, static and stable, or progressive with increasing loss of brain activity over time.

 

Find out more about Encephalopathy Treatment Landscape @ Drugs for Encephalopathy Treatment

 

Encephalopathy Emerging Drugs Profile

  • XEN496: Xenon Pharmaceuticals
  • AXA 1665: Axcella Health
  • RBX 7455: Rebiotix

 

Encephalopathy Pipeline Therapeutics Assessment

The Encephalopathy pipeline report proffers an integral view of the Encephalopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Encephalopathy Pipeline Therapies @ Encephalopathy Clinical Trials Assessment

 

Scope of the Encephalopathy Pipeline Report

  • Coverage- Global
  • Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Encephalopathy Companies- Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
  • Encephalopathy Pipeline Therapies- RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.

 

Dive deep into rich insights for new drugs for Encephalopathy Treatment, Visit @ Encephalopathy Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Encephalopathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Encephalopathy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. XEN496: Xenon Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RBX 7455: Rebiotix
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name; Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Encephalopathy Key Companies
  21. Encephalopathy Key Products
  22. Encephalopathy – Unmet Needs
  23. Encephalopathy – Market Drivers and Barriers
  24. Encephalopathy – Future Perspectives and Conclusion
  25. Encephalopathy Analyst Views
  26. Encephalopathy Key Companies
  27. Appendix

 

For further information on the Encephalopathy Pipeline therapeutics, reach out to Encephalopathy Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Encephalopathy Pipeline Insights Report 2024 | Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, and others.

Hemophilia A Pipeline Insights Report 2024

DelveInsight’s, “Hemophilia A Pipeline Insight 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Hemophilia A Pipeline Report

  • DelveInsight’s Hemophilia A pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Hemophilia A treatment.
  • The leading companies working in the Hemophilia A Market include Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.
  • Promising Hemophilia A Pipeline Therapies in the various stages of development include Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.
  • July 2023: Apcintex Ltd announced a study of phase 2 clinical trials for SerpinPC. The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of prophylactic SerpinPC administered subcutaneously (SC) to participants with severe hemophilia A (HemA) (with or without inhibitors) or moderately severe to severe hemophilia B (HemB) (without inhibitors) as part of the SerpinPC registrational program.
  • September 2023: Swedish Orphan Biovitrum announced a study of phase 4 clinical trials for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc.

 

Request a sample and discover the recent advances in Hemophilia A Treatment Drugs @ Hemophilia A Pipeline Report

 

In the Hemophilia A pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemophilia A collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Hemophilia A Overview

Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. This disorder can be severe, moderate, or mild. In severe cases, heavy bleeding occurs after minor injury or even when there is no injury (spontaneous bleeding).

 

Find out more about Hemophilia A Treatment Landscape @ Drugs for Hemophilia A Treatment

 

Hemophilia A Emerging Drugs Profile

  • AGN-193408: Allergan
  • OCTA101: Octapharma
  • Valoctocogene roxaparvovec: BioMarin Pharmaceuticals

 

Hemophilia A Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Hemophilia A therapies. The Hemophilia A companies which have their Hemophilia A drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd. and others.

 

Learn more about the emerging Hemophilia A Pipeline Therapies @ Hemophilia A Clinical Trials Assessment

 

Scope of the Hemophilia A Pipeline Report

  • Coverage- Global
  • Hemophilia A Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hemophilia A Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Hemophilia A Companies- Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenix pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics LLC, CSL Behring, and others.
  • Hemophilia A Pipeline Therapies- Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.

 

Dive deep into rich insights for new drugs for Hemophilia A treatment, Visit @ Hemophilia A Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hemophilia A: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hemophilia A – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Hemophilia A Collaboration Deals
  9. Late Stage Products (Pre-registration)
  10. Valoctocogene roxaparvovec: BioMarin Pharmaceutical
  11. Late Stage Products (Phase III)
  12. Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics
  13. Mid Stage Products (Phase II)
  14. NNC0365-3769 A (Mim8): Novo Nordisk A/S
  15. Early Stage Products (Phase I/II)
  16. BAX 888: Baxalta / Shire
  17. BAY2599023: Bayer / Ultragenix pharmaceutical
  18. Early Stage Products (Phase I)
  19. Gene therapy: Expression Therapeutics, LLC
  20. Drug profiles in the detailed report…..
  21. Hemophilia A- Market Drivers and Barriers
  22. Appendix

 

For further information on the Hemophilia A pipeline therapeutics, reach out to Hemophilia A Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia A Pipeline Insights Report 2024

Dry Age-Related Macular Degeneration Pipeline Insights Report 2024 | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals

DelveInsight’s, “Dry Age-related Macular Degeneration Pipeline Insight 2024”  report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report

  • DelveInsight’s Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-Related Macular Degeneration treatment.
  • The leading companies working in the Dry Age-Related Macular Degeneration market include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
  • Promising Dry Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
  • On January 2023, Luxa Biotechnology Inc. announced a study of Phase 1 & 2 Clinical Trials for RPESC-RPE-4W. The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
  • On August 2023, Smilebiotek Zhuhai Limited announced a study of Phase 2 Clinical Trials for QA102. This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes.

 

Request a sample and discover the recent advances in Dry Age-Related Macular Degeneration Treatment Drugs @ Dry Age-Related Macular Degeneration Pipeline Outlook Report

 

The Dry Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-Related Macular Degeneration clinical trial landscape.

 

Dry Age-Related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons.

 

Find out more about Dry Age-Related Macular Degeneration Treatment Landscape @ Drugs for Dry Age-Related Macular Degeneration Treatment

 

Dry Age-Related Macular Degeneration Emerging Drugs Profile

  • Tinlarebant (LBS-008): Belite Bio
  • XIFLAM: Inflammx Therapeutics
  • OCU410: Ocugen
  • OLX301A: OliX Pharmaceuticals
  • GS030: Gensight Biologics

 

Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The Dry Age-Related Macular Degeneration companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.

 

Learn more about the emerging Dry Age-Related Macular Degeneration Pipeline Therapies @ Dry Age-Related Macular Degeneration Clinical Trials Assessment

 

Scope of the Dry Age-Related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Dry Age-Related Macular Degeneration Companies- Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
  • Dry Age-Related Macular Degeneration Pipeline Therapies- RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.

 

Dive deep into rich insights for new drugs for Dry Age-Related Macular Degeneration Treatment, Visit @ Dry Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dry Age-related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dry Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Abicipar pegol: Molecular Partners
  9. Late Stage Products (Phase III)
  10. ALK-001: Alkeus Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Elamipretide: Stealth BioTherapeutics
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. AAV.sFH: Aevitas Therapeutics
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Dry Age-related Macular Degeneration Key Companies
  23. Dry Age-related Macular Degeneration Key Products
  24. Dry Age-related Macular Degeneration- Unmet Needs
  25. Dry Age-related Macular Degeneration- Market Drivers and Barriers
  26. Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
  27. Dry Age-related Macular Degeneration Analyst Views
  28. Dry Age-related Macular Degeneration Key Companies
  29. Appendix

 

For further information on the Dry Age-Related Macular Degeneration Pipeline therapeutics, reach out to Dry Age-Related Macular Degeneration Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Age-Related Macular Degeneration Pipeline Insights Report 2024 | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals

Cystic Fibrosis Pipeline Insights Report 2024 | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.

DelveInsight’s, “Cystic Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Cystic Fibrosis Pipeline Report

  • DelveInsight’s Cystic Fibrosis pipeline report depicts a robust space with 75+ companies working to develop 80+ pipeline therapies for Cystic Fibrosis treatment.
  • The leading companies working in the Cystic Fibrosis Market include Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
  • Promising Cystic Fibrosis Pipeline Therapies in the various stages of development include Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.
  • October 2023: Vertex Pharmaceuticals Incorporated announced a study of phase 3 clinical trials for ELX/TEZ/IVA and IVA. This study will evaluate the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF subjects 12 to less than (<) 24 months of age.
  • September 2023: Cystetic Medicines, Inc. announced a study of phase 1 clinical trials for ABCI. This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part B), and a Phase 1b open-label study in subjects with CF (Part C) to assess the safety, tolerability, PK, and preliminary efficacy of ABCI. Subjects will be evaluated for eligibility during Screening within 30 days before Day 1 (Randomization; Visit 3).

 

Request a sample and discover the recent advances in Cystic Fibrosis Treatment Drugs @ Cystic Fibrosis Pipeline Report

 

In the Cystic Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Cystic Fibrosis Overview

Cystic fibrosis is a progressive, genetic disease that causes long-lasting lung infections and limits the ability to breathe over time. More than 30,000 children and adults in the United States have CF (70,000 worldwide) and CF affects people of every racial and ethnic group.

 

Find out more about Cystic Fibrosis Therapeutics Assessment @ Cystic Fibrosis Preclinical and Discovery Stage Products

 

Cystic Fibrosis Emerging Drugs Profile

  • OligoG: Algi Pharma
  • Ensifentrine: Verona Pharma
  • MRT5005: Translate Bio
  • CB280: Calithera Biosciences
  • KB407 : Krystal Biotech
  • SPL84231: SpliSense

 

Cystic Fibrosis Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Cystic Fibrosis therapies. The Cystic Fibrosis companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Algi Pharma.

 

Learn more about the emerging Cystic Fibrosis Pipeline Therapies @ Cystic Fibrosis Clinical Trials Assessment

 

Scope of the Cystic Fibrosis Pipeline Report

  • Coverage- Global
  • Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Cystic Fibrosis Companies- Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxosmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
  • Cystic Fibrosis Pipeline Therapies- Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.

 

Dive deep into rich insights for new drugs for Cystic Fibrosis Treatment, Visit @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cystic Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cystic Fibrosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. OligoG : Algi pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CB280:Calithera Biosciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SPL84231: Spli Sense
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cystic Fibrosis Key Companies
  21. Cystic Fibrosis Key Products
  22. Cystic Fibrosis Unmet Needs
  23. Cystic Fibrosis Market Drivers and Barriers
  24. Cystic Fibrosis Future Perspectives and Conclusion
  25. Cystic Fibrosis Analyst Views
  26. Cystic Fibrosis Companies
  27. Appendix

 

For further information on the Cystic Fibrosis Pipeline therapeutics, reach out to Cystic Fibrosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystic Fibrosis Pipeline Insights Report 2024 | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.